Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04181827
Title	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
Acronym	CARTITUDE-4
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	No
Sponsors	Janssen Research & Development, LLC
Indications	multiple myeloma
Therapies	Daratumumab + Dexamethasone + Pomalidomide Bortezomib + Dexamethasone + Pomalidomide Bortezomib + Ciltacabtagene autoleucel + Cyclophosphamide + Dexamethasone + Fludarabine + Pomalidomide Ciltacabtagene autoleucel + Cyclophosphamide + Daratumumab + Dexamethasone + Fludarabine + Pomalidomide
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| POL \| NLD \| ITA \| ISR \| GRC \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL \| AUS